The combination of CXCR4 antagonists (such as plerixafor or balixafortide) with standard chemotherapeutics (e.g., paclitaxel, doxorubicin, or cisplatin) makes TNBC cells more sensitive to treatment by inhibiting stromal protection, decreasing the maintenance of cancer stem cells, and promoting apoptosis [24]. This evidence concerns the gene CXCR4 and cancer.